Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
Stephen S. Whitehead, Montgomery Village, MD (US); Brian R. Murphy, Bethesda, MD (US); Lewis Markoff, Bethesda, MD (US); Barry Falgout, Rockville, MD (US); Joseph Blaney, Gettysburg, PA (US); Kathryn Hanley, Las Cruces, NM (US); and Ching-Juh Lai, Bethesda, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Bethesda, MD (US)
Filed on Sep. 1, 2020, as Appl. No. 17/9,448.
Application 17/009,448 is a division of application No. 15/710,672, filed on Sep. 20, 2017, granted, now 10,837,003.
Application 15/710,672 is a continuation of application No. 13/305,639, filed on Nov. 28, 2011, granted, now 9,783,787, issued on Oct. 10, 2017.
Application 13/305,639 is a continuation of application No. 12/398,043, filed on Mar. 4, 2009, granted, now 8,075,903, issued on Dec. 13, 2011.
Application 12/398,043 is a continuation of application No. 10/970,640, filed on Oct. 21, 2004, granted, now 7,517,531, issued on Apr. 14, 2009.
Application 10/970,640 is a continuation of application No. PCT/US03/13279, filed on Apr. 25, 2003.
Claims priority of provisional application 60/436,500, filed on Dec. 23, 2002.
Claims priority of provisional application 60/377,860, filed on May 3, 2002.
Prior Publication US 2020/0392469 A1, Dec. 17, 2020
1. A nucleic acid encoding a Dengue 3 virus comprising a deletion of nucleotides from the 3′ untranslated region of the Dengue 3 genome corresponding to the TL2 stem-loop structure between nucleotides 10535-10565 of SEQ ID NO: 48.